Targeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEF

HFpEF 中的靶向骨骼肌灌注和氧化能力

• 批准号: 10625968
• 负责人: Payman Zamani
• 金额: $ 78.75万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10625968
• 关键词: Acceleration; Acetylcarnitine; Address; Aerobic; Biochemical; Biopsy Specimen; Blood; Clinical Trials; Combined Modality Therapy; Complex; Cross-Over Trials; Data; Double-Blind Method; Drug Combinations; EFRAC; Exercise; Exercise Tolerance; Exertion; Goals; Heart failure; Heterogeneity; Impairment; Individual; Intervention; Intramuscular; Kinetics; Left; Levocarnitine; Life; Magnetic Resonance Imaging; Measurement; Measures; Metabolic; Mitochondria; Movement; Muscle; Nitrates; Oxidative Phosphorylation; Oxygen; Patients; Perfusion; Persons; Pharmacotherapy; Phenotype; Potassium Chloride; Process; Production; Quality of life; Randomized; Skeletal Muscle; Syndrome; Techniques; Testing; Therapeutic; Therapeutic Intervention; Time; Translating; Work; active control; diagnostic strategy; disability; endurance exercise; exercise capacity; impaired capacity; improved; individual response; insight; nicotinamide-beta-riboside; novel; novel diagnostics; novel therapeutics; pharmacologic; potassium nitrate; preservation; prevent; primary endpoint; propionyl-coenzyme A; response; secondary endpoint; success; supplemental oxygen; treatment response; uptake

SUMMARY: Heart Failure with Preserved Ejection Fraction (HFpEF) is on pace to become the dominant form of heart failure, yet we have no treatments to offer patients. Our preliminary data suggest that abnormalities in skeletal muscle oxidative phosphorylation capacity (SM OxPhos) may contribute to exertional intolerance. SM OxPhos is a complex metric, incorporating both (a) intramuscular perfusion and (b) mitochondrial oxidative reserve capacity, suggesting that both need to be measured to understand the mechanism underlying SM OxPhos impairment. Our group has developed novel MRI sequences which can evaluate both measures. Moreover, we have identified a unique metabolite signature in skeletal muscle biopsy samples from HFpEF patients: a reduction in NAD+ and Propionyl-CoA, indicating metabolic perturbations that may lead to energetic deficits and impair mitochondrial reserve. The goal of this proposal is to investigate the relationship between SM OxPhos and submaximal exercise endurance in HFpEF, with the scientific premise that improvements in SM OxPhos will translate into improvements in exercise endurance. We focus on submaximal exercise endurance as this better reflects the level of exertion reached by HFpEF patients during daily activities. In Aim 1: We will test three interventions in 53 subjects with HFpEF in a cross-over trial: (1) Potassium nitrate (KNO3), which predominantly targets exercise intramuscular perfusion; (2) The combination of KNO3 with nicotinamide riboside (NR) and Propionyl-L-Carnitine (PLC), which targets both intramuscular perfusion and mitochondrial oxidative reserve capacity by replenishing the identified metabolite deficiencies; and (3) Potassium chloride (active control). We hypothesize that while both KNO3 and combination therapy will improve submaximal exercise endurance, combination therapy will lead to greater overall increases. We will also assess the impact of our interventions on SM OxPhos, and the relationship between SM OxPhos and submaximal exercise endurance. In Aim 2: we will test a new diagnostic strategy to identify the mechanism underlying a specific HFpEF patient’s impaired SM OxPhos: the response to supplemental oxygen (100% O2). The lack of SM OxPhos response to oxygen suggests that an impairment in mitochondrial reserve is preventing the utilization of additional oxygen. We hypothesize that these patients will derive greater benefit from combination therapy (KNO3+NR+PLC) by addressing mitochondrial reserve in addition to increasing intramuscular perfusion. Our proposal will comprehensively assess the relationship between SM OxPhos and submaximal exercise endurance using complimentary techniques. It will test novel therapeutics, with the primary goal of improving submaximal exercise endurance and also identify which patients should be treated with which therapy. This proposal has the potential to change the landscape of HFpEF therapeutics, giving us a mechanistically rational strategy to offer relief to these otherwise limited patients.

摘要：射血分数保留性心力衰竭（HFpEF）正在成为主要形式 但是我们没有治疗方法可以提供给病人我们的初步数据表明， 骨骼肌氧化磷酸化能力（SM OxPhos）可能有助于运动不耐受。SM OxPhos是一个复杂的指标，包括（a）肌内灌注和（B）线粒体氧化 储备能力，这表明两者都需要进行测量，以了解SM的机制 OxPhos损伤。我们的研究小组已经开发了新的MRI序列，可以评估这两种措施。 此外，我们在HFpEF的骨骼肌活检样本中发现了一种独特的代谢物特征， 患者：NAD+和丙酰辅酶A减少，表明可能导致能量代谢紊乱的代谢紊乱 缺陷和受损的线粒体储备。 本提案的目的是调查SM OxPhos和次极量运动之间的关系 HFpEF的耐力，科学前提是SM OxPhos的改善将转化为 提高运动耐力。我们专注于次极量运动耐力，因为这更好地反映了 HFpEF患者在日常活动中达到的运动水平。目标1：我们将测试三种干预措施， 交叉试验中的53例HFpEF受试者：（1）硝酸钾（KNO 3），主要针对运动 肌内灌流;（2）硝酸钾与烟酰胺核苷（NR）和丙酰-L-肉毒碱联合应用 (PLC)，其通过补充肌内灌注和线粒体氧化储备能力， 确定的代谢物缺乏;和（3）氯化钾（活性对照）。我们假设 KNO 3和联合治疗将改善亚极量运动耐力，联合治疗将导致 整体增幅更大。我们还将评估我们的干预措施对SM OxPhos的影响，以及它们之间的关系。 和次极量运动耐力之间的关系目标2：我们将测试一种新的诊断策略， 确定特定HFpEF患者SM OxPhos受损的潜在机制： 补充氧气（100% O2）。SM OxPhos对氧气反应的缺乏表明， 线粒体储备阻止了额外氧气的利用。我们假设这些病人 通过解决线粒体储备，从联合治疗（KNO 3 +NR+PLC）中获得更大的益处， 增加肌内灌注。 我们的建议将全面评估SM OxPhos和次最大剂量之间的关系。 使用辅助技术锻炼耐力。它将测试新的治疗方法，主要目标是 改善亚极量运动耐力，并确定哪些患者应采用何种疗法治疗。 这项提议有可能改变HFpEF治疗的前景，给我们一个机械的 合理的策略，以提供救济，以这些否则有限的病人。

项目成果

Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction.

• DOI: 10.3389/fcvm.2022.1016452
• 发表时间: 2022
• 期刊: Frontiers in cardiovascular medicine
• 影响因子: 3.6

Prospective Evaluation of Cardiovascular Risk 10 Years After a Hypertensive Disorder of Pregnancy.

• DOI: 10.1016/j.jacc.2022.03.383
• 发表时间: 2022-06-21
• 期刊: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
• 影响因子: 24
• 作者: Levine, Lisa D.;Ky, Bonnie;Chirinos, Julio A.;Koshinksi, Jessica;Arany, Zoltan;Riis, Valerie;Elovitz, Michal A.;Koelper, Nathanael;Lewey, Jennifer
• 通讯作者: Lewey, Jennifer

Predictive Ability of Pressure-Corrected Arterial Stiffness Indices: Comparison of Pulse Wave Velocity, Cardio-Ankle Vascular Index (CAVI), and CAVI0.

• DOI: 10.1093/ajh/hpab168
• 发表时间: 2022-03-08
• 期刊: American journal of hypertension
• 影响因子: 3.2
• 作者: Spronck B;Obeid MJ;Paravathaneni M;Gadela NV;Singh G;Magro CA;Kulkarni V;Kondaveety S;Gade KC;Bhuva R;Kulick-Soper CM;Sanchez N;Akers S;Chirinos JA
• 通讯作者: Chirinos JA

Arterial Stiffness and Diabetes Risk in Framingham Heart Study and UK Biobank.

• DOI: 10.1161/circresaha.122.320796
• 发表时间: 2022-09-02
• 期刊: Circulation research
• 影响因子: 20.1
• 作者: Cohen JB;Mitchell GF;Gill D;Burgess S;Rahman M;Hanff TC;Ramachandran VS;Mutalik KM;Townsend RR;Chirinos JA
• 通讯作者: Chirinos JA

Association of blood pressure variability with Endothelin-1 by menopause status among Black women: findings from the Jackson Heart Study.

黑人女性绝经状态下血压变异性与内皮素 1 的关联：杰克逊心脏研究的结果。

• DOI: 10.1038/s41371-023-00824-y
• 发表时间: 2023
• 期刊: Journal of human hypertension
• 影响因子: 2.7
• 作者: Rethy,Leah;Polsinelli,VincenzoB;Muntner,Paul;Bello,NatalieA;Cohen,JordanaB
• 通讯作者: Cohen,JordanaB